bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies - Pharmaceutical Technology
Bluebird Bio Withdraws Zynteglo From Germany Over Pricing :: Pink Sheet
At $2.8 Million, Beti-cel Is a Canary in the Drug Cost Coal Mine
ZYNTEGLO® (betibeglogene autotemcel)
Zynteglo: Gene Therapy for Beta-thalassemia • BioPharma Media
blue-ex992_54.htm
FDA Approves Bluebird's $2.8 Million Gene Therapy for Rare Blood Disease - WSJ
ICER Draft Evidence Report on Bluebird Gene Therapy Zynteglo Finds It Provides Value at $2.1 Million - Global Genes
FDA approves bluebird bio's Zynteglo for beta-thalassemia - BIO.News
Bluebird Bio Resumes Marketing Of Gene Therapy Zynteglo For β-Thalassaemia In Europe – TIF
FDA Approves $2.8 million Gene Tx - Zynteglo - Anton Health
bluebird bio to Resume Marketing of ZYNTEGLO in EU
NEW | Bluebirdbio Releases Resources For Patients On Gene Therapy Zynteglo® – TIF
bluebird bio Inc., Undervalued Acquisition Candidate (NASDAQ:BLUE) | Seeking Alpha
FDA Approves bluebird bio's ZYNTEGLO®, the First Gene Therapy for People with Transfusion-Dependent Beta-Thalassemia - The Cooley's Anemia Foundation
bluebird bio Launches Gene Therapy for Severe Blood Disorder in Germany | North Carolina Biotechnology Center
Bluebird wins U.S. approval for gene therapy for beta thalassemia - STAT
Bluebird bio's gene therapy Zynteglo could have high price tag defense in beta thalassemia - Pharmaceutical Technology
Bluebird's $2.8M gene therapy Zynteglo gets FDA backing
Bluebird Bio CEO defends $1.8 million price tag for new gene therapy
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions | Business Wire
bluebird bio gets CHMP nod for gene therapy Zynteglo | Pharmaphorum
Bluebird bio announces 1st commercial launch of ZYNTEGLO™in Germany – TIF
Somerville gene therapy firm bluebird bio nabs win with first FDA approval following split - Boston Business Journal
bluebird bio's Zynteglo gene therapy receives FDA approval
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions - bluebird bio, Inc.
